Clinical trials
Lung Cancer, Non-Small Cell clinical trials
Below are recruiting lung cancer, non-small cell clinical trials, each written for real people, not researchers. We’re tracking 1,098 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05985330Recruiting
Study of FeNO as a marker for immunotherapy response in lung cancer
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
DijonAges 18 years+ - NCT05990946Recruiting
Smartphone symptom check-ins to improve recovery exercises after lung surgery
This trial tests whether using a smartphone app to report symptoms can help patients stick to their recovery exercises after minimally invasive lung cancer surgery. If you are having surgery for lung cancer, this study may help you recover better at home.
Zhongshan, GuangdongAges 18–75 - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Birmingham, AlabamaAges 18 years+ - NCT05965557Recruiting
Markers that predict response to immunotherapy before lung surgery
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
ShanghaiAges 18–80 - NCT05920356RecruitingPhase 3
Tested KRAS-targeted sotorasib plus chemo vs pembrolizumab plus chemo
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
Santa Barbara, CaliforniaAges 18–100 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT05935384Recruiting
Blood tests to track response to cancer therapy
This study follows how cancer responds to standard (usual) treatment by using blood samples and de-identified health data. It may help researchers understand whether “liquid biopsy” blood testing can reflect how well therapy is working.
Skokie, IllinoisAges 18 years+ - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT05933239RecruitingPhase 2
PET-like scan using a special protein in lung cancer
This Phase 2 study tests whether a new imaging medicine (a radiopharmaceutical) can highlight immune cells called macrophages in people with non-small cell lung cancer. It may help doctors better “see” and evaluate tumor tissue before a surgical biopsy or removal.
Jette, Brussels CapitalAges 18 years+ - NCT04900935Recruiting
Survivorship and palliative care planning for metastatic lung cancer
This study tests a more patient-centered way to plan survivorship care and comfort (palliative) care for people with metastatic lung cancer. It may help you get support that matches your goals, especially alongside your current targeted treatment.
Boston, MassachusettsAges 18 years+ - NCT05889247Recruiting
Blood test guided monitoring for advanced lung cancer treatment
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
Hillerød, Region HAges Any age - NCT05886439RecruitingPhase 1/Phase 2
Study drug plus PD-1 or PD-L1 for lung cancer
This Phase 1/2 trial tests a new treatment called LK101 combined with a PD-1 or PD-L1 antibody for advanced lung cancer. It may help shrink tumors and improve control of the disease, especially after prior anti–PD-1/PD-L1 treatment has stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05885698Recruiting
Study of care patterns in newly diagnosed lung cancer
This observational study follows adults with newly diagnosed non-small cell lung cancer to understand what treatments are used and how patients are doing. It may help doctors better understand how care decisions affect outcomes, and it does not require the study to give an experimental treatment.
Daphne, AlabamaAges 18 years+ - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT05852990RecruitingPhase 3
Gut help to prevent diarrhea from EGFR-targeted lung cancer drugs
This Phase 3 trial tests whether adding glutamine plus L. reuteri can help prevent severe diarrhea caused by EGFR-targeted treatments in people with advanced non-small cell lung cancer. If it works, it could make treatment easier to tolerate and help you stay on the planned therapy.
Mexico City, Mexico CityAges 18–80 - NCT05864794Recruiting
Screening brain MRI in advanced lung cancer patients
This trial looks at whether doing an MRI scan of the brain for people with stage IV lung cancer helps in their care. The goal is to find brain issues early (if present) so treatment decisions can be made sooner.
Groningen, Provincie GroningenAges 18 years+ - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100 - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Basking Ridge, New JerseyAges 18 years+ - NCT04063501Recruiting
Study of gut microbes during immunotherapy for lung cancer
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
New York, New YorkAges 18–100 - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05798845RecruitingPhase 2
Toripalimab plus radiation before surgery for stage II–IIIA lung cancer
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05800587RecruitingPhase 2
Reduced-dose chemotherapy for advanced lung cancer
This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer, non-small cell?
- Yes. Clin2 currently lists 1,098 recruiting lung cancer, non-small cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer, non-small cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer, non-small cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.